Alpha Cognition EBITDA per Share

What does Alpha Cognition do? Alpha Cognition Inc develops treatments for neurodegenerative diseases including Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company's pipeline features ALPHA-1062, a patented acetylcholinesterase inhibitor for Alzheimer's disease with minimal gastrointestinal side effects, and ALPHA-0602, a gene therapy program delivering progranulin for ALS treatment in preclinical development. ALPHA-1062 is also being developed in combination with memantine for moderate to severe Alzheimer's dementia and as an intranasal formulation for traumatic brain injury. The company's products target patients suffering from these conditions, with ALPHA-1062 expected to address unmet medical needs in Alzheimer's treatment. Alpha Cognition's revenue streams primarily come from the development and potential future commercialization of its drug candidates. The company's pipeline includes ALPHA-1062, ALPHA-0602, ALPHA-0702, and ALPHA-0802 (GEMs), with ALPHA-1062 being the most advanced. The company's focus on underserved neurodegenerative diseases positions its products for potential partnerships and licensing agreements with larger pharmaceutical companies seeking to expand their neurological treatment portfolios. The firm's primary customers are patients suffering from neurodegenerative diseases, though the company generates revenue through partnerships and licensing deals rather than direct sales. ALPHA-1062's development in combination with memantine targets a specific segment of Alzheimer's patients requiring moderate to severe treatment, while the intranasal formulation targets traumatic brain injury patients. The company's preclinical development of ALPHA-0602 for ALS positions it to enter a market with significant unmet need. Alpha Cognition is one of the most popular companies on Eulerpool.